Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Isis Earns AstraZeneca Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Isis Earns AstraZeneca Milestone

ISIS-STAT3Rx advances to Phase II trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $7.5 million milestone payment from AstraZeneca for the advancement of ISIS-STAT3Rx (AZD9150) in patients with advanced cancers. Isis will earn the second $7.5 million milestone upon initiation of a Phase II study.  AstraZeneca is currently evaluating ISIS-STAT3Rx in a Phase 1/2 study in patients with advanced metastatic liver cancer.  AstraZeneca plans to initiate additional clinical studies to further evaluate ISIS-STAT3Rx.
 
In total, Isis is eligible to receive as much as $70 million in milestone payments for the advancement of ISIS-STAT3Rx, and as much as $170 million in regulatory milestones plus royalties on sales.
 
“AstraZeneca’s expertise and resources in the area of oncology drug development are a significant benefit for the clinical development of ISIS-STAT3Rx,” said B. Lynne Parshall, chief operating officer at Isis Pharmaceuticals.  “We are pleased, not only with the substantial resources and expertise that AstraZeneca has brought to this program, but also with their commitment to advancing ISIS-STAT3Rx into clinical development.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics